Connection

Eric Meissner to Humans

Back to Details
This is a "connection" page, showing publications Eric Meissner has written about Humans.
Eric Meissner
Connection Strength
0.665
Humans
  1. Association of Referral Source and Substance Use with Hepatitis C Virus Outcomes at a Southern Academic Medical Center. South Med J. 2022 06; 115(6):352-357.
    View in: PubMed
    Score: 0.032
  2. Self-administered, remote assessment of SARS-CoV-2 seroprevalence in health care workers. Am J Med Sci. 2022 Sep; 364(3):281-288.
    View in: PubMed
    Score: 0.032
  3. Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome. J Viral Hepat. 2021 11; 28(11):1614-1623.
    View in: PubMed
    Score: 0.031
  4. Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. Viruses. 2021 06 09; 13(6).
    View in: PubMed
    Score: 0.030
  5. Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis. 2020 Dec 04; 20(1):929.
    View in: PubMed
    Score: 0.029
  6. IFNL4 Genotype Does Not Associate with CD4 T-Cell Recovery in People Living with Human Immunodeficiency Virus. AIDS Res Hum Retroviruses. 2021 03; 37(3):184-188.
    View in: PubMed
    Score: 0.029
  7. Longitudinal analysis of serum microRNAs as predictors of cirrhosis regression during treatment of hepatitis B virus infection. Liver Int. 2020 07; 40(7):1693-1700.
    View in: PubMed
    Score: 0.028
  8. Increasing Prevalence of Chronic Hepatitis C Virus Infection in a Southern Academic Obstetrical Clinic. South Med J. 2019 06; 112(6):325-330.
    View in: PubMed
    Score: 0.026
  9. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019 03; 26(3):323-328.
    View in: PubMed
    Score: 0.025
  10. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression? Clin Infect Dis. 2018 08 31; 67(6):878-880.
    View in: PubMed
    Score: 0.025
  11. Association of Substance Use With Hospitalization and Virologic Suppression in a Southern Academic HIV Clinic. Am J Med Sci. 2018 06; 355(6):553-558.
    View in: PubMed
    Score: 0.024
  12. Across state lines: Fulminant Babesia microti infection in a liver transplant recipient. Transpl Infect Dis. 2017 Oct; 19(5).
    View in: PubMed
    Score: 0.023
  13. Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):120-127.
    View in: PubMed
    Score: 0.023
  14. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int. 2016 12; 36(12):1783-1792.
    View in: PubMed
    Score: 0.022
  15. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016 07; 23(7):496-505.
    View in: PubMed
    Score: 0.021
  16. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. PLoS One. 2015; 10(7):e0133236.
    View in: PubMed
    Score: 0.020
  17. Continued value in understanding viral kinetic decline during interferon-free therapy for HCV. Liver Int. 2015 Feb; 35(2):295-6.
    View in: PubMed
    Score: 0.020
  18. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015 Mar; 61(3):790-801.
    View in: PubMed
    Score: 0.019
  19. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014 Aug; 124(8):3352-63.
    View in: PubMed
    Score: 0.019
  20. IFNL4-?G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014 Jun 01; 209(11):1700-4.
    View in: PubMed
    Score: 0.018
  21. Disseminated microsporidiosis in an immunosuppressed patient. Emerg Infect Dis. 2012 Jul; 18(7):1155-8.
    View in: PubMed
    Score: 0.016
  22. Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the human thymus. J Virol. 2006 Nov; 80(22):11019-30.
    View in: PubMed
    Score: 0.011
  23. Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry. Virology. 2005 Jun 05; 336(2):184-97.
    View in: PubMed
    Score: 0.010
  24. Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. Virology. 2004 Oct 10; 328(1):74-88.
    View in: PubMed
    Score: 0.010
  25. HIV-1 replication and pathogenesis in the human thymus. Curr HIV Res. 2003 Jul; 1(3):275-85.
    View in: PubMed
    Score: 0.009
  26. Perspectives of HIV specialists and cardiologists on the specialty referral process for people living with HIV: a qualitative descriptive study. BMC Health Serv Res. 2022 May 09; 22(1):623.
    View in: PubMed
    Score: 0.008
  27. Prevention of cardiovascular disease for historically marginalized racial and ethnic groups living with HIV: A narrative review of the literature. Prog Cardiovasc Dis. 2020 Mar - Apr; 63(2):142-148.
    View in: PubMed
    Score: 0.007
  28. IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. J Immunol. 2017 12 01; 199(11):3808-3820.
    View in: PubMed
    Score: 0.006
  29. Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy. J Infect Dis. 2017 07 01; 216(1):82-91.
    View in: PubMed
    Score: 0.006
  30. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Res. 2017 08; 144:281-285.
    View in: PubMed
    Score: 0.006
  31. Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. Biomed Res Int. 2017; 2017:2067479.
    View in: PubMed
    Score: 0.006
  32. Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines. Antiviral Res. 2017 02; 138:79-85.
    View in: PubMed
    Score: 0.006
  33. Cardiovascular Disease, Statins, and HIV. J Infect Dis. 2016 Oct 01; 214 Suppl 2:S83-92.
    View in: PubMed
    Score: 0.005
  34. Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels. J Clin Pharmacol. 2017 01; 57(1):118-124.
    View in: PubMed
    Score: 0.005
  35. Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis. Hepatol Int. 2016 Nov; 10(6):937-946.
    View in: PubMed
    Score: 0.005
  36. Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination. Vaccine. 2016 Apr 07; 34(16):1945-55.
    View in: PubMed
    Score: 0.005
  37. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Res Hum Retroviruses. 2016 May; 32(5):456-62.
    View in: PubMed
    Score: 0.005
  38. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015 Dec 15; 163(12):899-907.
    View in: PubMed
    Score: 0.005
  39. Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015 Aug; 70(8):2322-9.
    View in: PubMed
    Score: 0.005
  40. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31; 313(12):1232-9.
    View in: PubMed
    Score: 0.005
  41. Persistently elevated abnormal B-cell subpopulations and anti-core antibodies in patients co-infected with HIV/HCV who relapse. J Med Virol. 2015 Apr; 87(4):544-52.
    View in: PubMed
    Score: 0.005
  42. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015 Mar 21; 385(9973):1107-13.
    View in: PubMed
    Score: 0.005
  43. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014 Nov 04; 161(9):634-8.
    View in: PubMed
    Score: 0.005
  44. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013 Aug 28; 310(8):804-11.
    View in: PubMed
    Score: 0.004
  45. Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis. Sci China Life Sci. 2010 Feb; 53(2):195-203.
    View in: PubMed
    Score: 0.003
  46. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog. 2007 Aug 24; 3(8):e117.
    View in: PubMed
    Score: 0.003
  47. BRCA1-associated growth arrest is RB-dependent. Proc Natl Acad Sci U S A. 1999 Oct 12; 96(21):11866-71.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.